Guillain-Barré syndrome after bortezomib therapy in a child with relapsed acute lymphoblastic leukemia

  • Valeria Ceolin
  • , Rosita Cenna
  • , Francesca Resente
  • , Manuela Spadea
  • , Franca Fagioli
  • , Nicoletta Bertorello

Research output: Contribution to journalArticlepeer-review

Abstract

A 12-year-old male being treated for a high-risk relapsed T-acute lymphoblastic leukemia presented progressive weakness and numbness of both legs after having received a chemotherapy regimen that included bortezomib. Diagnosis of acute Guillain-Barré syndrome-like inflammatory demyelinating polyneuropathy was made following clinical examination, cerebrospinal fluid analysis, electrodiagnostic studies, magnetic resonance imaging, and serum immunoglobulin antibodies to anti-ganglioside. Intravenous immunoglobulin treatment was started, resulting in complete clinical recovery. Although in rare cases, Guillain-Barré syndrome after bortezomib therapy has been reported; this paper suggests that GBS may occur when bortezomib is administered and high‑dose intravenous immunoglobulin lead to a resolution of the symptoms.

Original languageEnglish
Pages (from-to)187-192
Number of pages6
JournalPediatric Hematology and Oncology
Volume39
Issue number2
DOIs
Publication statusPublished - 2022
Externally publishedYes

Keywords

  • Bortezomib
  • case report
  • Guillain-Barré syndrome
  • relapsed lymphoblastic leukemia
  • Magnetic Resonance Imaging
  • Immunoglobulins, Intravenous/therapeutic use
  • Bortezomib/adverse effects
  • Humans
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy
  • Guillain-Barre Syndrome/chemically induced
  • Child

Fingerprint

Dive into the research topics of 'Guillain-Barré syndrome after bortezomib therapy in a child with relapsed acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this